Five Stocks Draw Attention After Earnings, Trial Results and Merck Deal
Cleveland-Cliffs reported third-quarter adjusted EPS of 28 cents and projected fourth-quarter adjusted EBITDA of approximately $715 million. Disc Medicine reported positive Phase 3 results, Merck agreed to acquire Silence Therapeutics for approximately $1.3 billion in cash, and EyePoint announced plans to end its wet A